Why the study?
Understanding of the cardiac side effects of biological therapies is rapidly evolving, and cardiotoxicity is becoming increasingly significant as cancer patients achieve higher life expectancy with targeted agents.
What are the cardiovascular toxicities associated with novel biological therapies in cancer patients, and what are the strategies for their diagnosis and management?
Design
Review
Authors
Loading...
Cardiotoxicity vigilance is warranted with novel biologics in longer-surviving patients; leaves open prospective risk-stratification studies.
What are the cardiovascular toxicities associated with novel biological therapies in cancer patients, and what are the strategies for their diagnosis and management?
This review provides a comprehensive overview of the cardiotoxic effects of novel biological therapies in cancer patients, emphasizing the importance of early detection and timely intervention.
Madanat et al. (2022) studied this question.